The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure
Abstract
Background— In heart failure (HF), aldosterone has been implicated in the formation of reactive interstitial fibrosis, a maladaptation that contributes to left ventricular (LV) remodeling. Eplerenone is a novel selective aldosterone blocker. The present study examined the effects of long-term monotherapy with eplerenone on the progression of LV dysfunction and remodeling in dogs with chronic HF. Methods and Results— HF was produced in 14 dogs by intracoronary microembolizations that were discontinued when LV ejection fraction (EF) was between 30% and 40%. Two weeks after the last embolization, dogs were randomized to 3 months of oral therapy with eplerenone (10 mg/kg twice daily, n=7) or no therapy at all (control, n=7). Hemodynamic measurements were made just before randomization and were repeated at the end of 3 months of therapy. In control dogs, LV end-diastolic and end-systolic volume increased significantly (62±4 versus 68±4 mL, P <0.001, and 38±3 versus 47±3 mL, P <0.001, respectively), and EF decreased significantly (38±1% versus 31±2%, P <0.001). In contrast, end-diastolic volume, end-systolic volume, and EF remained unchanged during the 3 months of treatment in eplerenone-treated dogs. LV end-diastolic wall stress increased significantly in control dogs but decreased significantly in eplerenone-treated dogs. Compared with control, eplerenone was associated with a 28% reduction in cardiomyocyte cross-sectional area, a 37% reduction of volume fraction of reactive interstitial fibrosis, and a 34% reduction of volume fraction of replacement fibrosis. Conclusions— Our results indicate that long-term therapy with eplerenone prevents progressive LV dysfunction and attenuates LV remodeling in dogs with chronic HF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A. (1981) · Journal of Endocrinology · doi:10.1677/joe.0.0910457 · Cited by 339
Cited by
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
The renin-angiotensin-aldosterone system and its suppression
Ames, M. K., Atkins, C. E., & Pitt, B. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15454 · Cited by 433
Senni, M., Paulus, W. J., Gavazzi, A., Fraser, A. G., Diez, J., Solomon, S. D., Smiseth, O. A., Guazzi, M., Lam, C. S. P., Maggioni, A. P., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu204 · Cited by 355
Desai, A. S., Lewis, E. F., Li, R., Solomon, S. D., Assmann, S. F., Boineau, R., Clausell, N., Diaz, R., Fleg, J. L., Gordeev, I., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.09.007 · Cited by 274
Aldosterone Antagonism Attenuates Obesity-Induced Hypertension and Glomerular Hyperfiltration
de Paula, R. B., da Silva, A. A., & Hall, J. E. (2004) · Hypertension · doi:10.1161/01.hyp.0000105624.68174.00 · Cited by 207
Metadata
- Authors
- Suzuki, G., Morita, H., Mishima, T., Sharov, V. G., Todor, A., Tanhehco, E. J., Rudolph, A. E., McMahon, E. G., Goldstein, S., & Sabbah, H. N.
- Venue
- Circulation
- Published
- 2002-12-03
- Volume
- 106
- Issue
- 23
- Pages
- 2967-2972
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2006910397
- Cited by
- 218
- References
- 2
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure. https://app.cochat.ai/papers/10.1161/01.cir.0000039104.56479.42
- The paper
- Suzuki, G., Morita, H., Mishima, T., Sharov, V. G., Todor, A., Tanhehco, E. J., Rudolph, A. E., McMahon, E. G., Goldstein, S., & Sabbah, H. N. (2002). Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure. Circulation. https://doi.org/10.1161/01.cir.0000039104.56479.42
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.